Glucocorticoids suppress corticotropin-releasing hormone and vasopressin expression in human hypothalamic neurons

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 6, 1998, Pages 2066-2073

  Erkut, Zeynel A ^a   Pool, Chris ^a   Swaab, Dick F ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID; VASOPRESSIN;

ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CORTICOTROPIN RELEASE; FLUID BALANCE; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NEGATIVE FEEDBACK; PRIORITY JOURNAL; VASOPRESSIN RELEASE; WITHDRAWAL SYNDROME;

ADULT; AGED; ARGININE VASOPRESSIN; CORTICOTROPIN-RELEASING HORMONE; FEEDBACK; FEMALE; GLUCOCORTICOIDS; HUMANS; HYPOTHALAMUS; MALE; MIDDLE AGED; NEURONS; OXYTOCIN; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; POSTMORTEM CHANGES; PROTEIN PRECURSORS; SUPRAOPTIC NUCLEUS; VASOPRESSINS;

EID: 0031732902     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.6.2066     Document Type: Article

References (57)

1. Twycross R. 1994 The risks and benefits of glucocorticoids in advanced cancer. Drug Saf. 11:163-178.
2. Posner JB. 1992 Management of brain metastases. Rev Neurol. 148:477-487.
3. Axelrod L. 1976 Glucocorticoid therapy. Medicine. 55:39-65.
4. Miller DH, Thompson AJ, Morrissey SP, et al. 1992 High dose steroids in acute relapses of MS: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry. 55:450-453.
5. Lane SJ, Atkinson BA, Swaminathan R, Lee TH. 1996 HPA axis in glucocorticoid-resistant bronchial asthma. Am J Respir Crit Care Med. 153:557-560.
6. Munck A, Guyre PM, Holbrook NJ. 1984 Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev. 5:25-44.
7. DeBold CR, Sheldon WR, DeCherney GS, et al. 1984 Arginine vasopressin potentiates ACTH release induced by ovine corticotropin-releasing factor. J Clin Invest. 73:533-538.
8. Chrousos GP. 1995 The HPA axis and immune-mediated inflammation. Seminars in medicine of the Beth Israel hospital, Boston. N Engl J Med. 332:1351-1362.
9. Michelson D, Stone L, Galliven E, et al. 1994 MS is associated with alterations in HPA axis function. J Clin Endocrinol Metab. 79:848-853.
10. MacPhee IA, Antoni FA, Mason DW. 1989 Spontaneous recovery of rats from EAE is dependent on regulation of the immune system by endogenous glucocorticoids. J Exp Med. 169:431-445.
11. Mason D. 1991 Genetic variation in the stress response: susceptibility to EAE and implications for human inflammatory disease. Immunol Today. 12:57-60.
12. Karalis K, Crofford L, Wilder RL, Chrousos GP. 1995 Glucocorticoid and/or glucocorticoid antagonist effects in inflammatory disease-susceptible Lewis rats and inflammatory disease-resistant Fischer rats. Endocrinology. 136:3107-3112.
13. Wolkowitz OM. 1994 Prospective controlled studies of the behavioral and biological effects of exogenous glucocorticoids. Psychoneuroendocrinology. 19:233-355.
14. Wolkowitz OM, Reus VI, Weingartner H, et al. 1990 Cognitive effects of glucocorticoids. Am J Psychiatry. 147:1297-1303.
15. Gift AG, Wood RM, Cahill CAC. 1989 Depression, somatization and steroid use in chronic obstructive pulmonary disease. Int J Nurs Stud. 26:281-286.
16. Bräunig P, Bleistein J, Rao ML. 1989 Suicidality and glucocorticoid-induced psychosis. Biol Psychiatry. 26:209-220.
17. Martignoni E, Costa A, Sinforiani E, et al. 1992 The brain as a target for adrenocortical steroids: cognitive implications. Psychoneuroendocrinology. 17:343-354.
18. Imam AP, Halpern GM. 1995 Uses, adverse effects of abuse of glucocorticoids, part 2. Allergy Immunopathol. 23:2-15.
19. Melby JC. 1974 Systemic corticosteroid therapy: pharmacology and endocrinologic considerations. Ann Intern Med. 81:505-512.
20. Wenning GK, Wietholter H, Schnauder G, Muller PH, Kanduth S, Renn W. 1994 Recovery of the HPA axis from suppression by short-term, high-dose intravenous prednisolone therapy in patients with MS. Acta Neurol Scand. 89:270-273.
21. Dixon RB, Christy NP. 1980 On the various forms of glucocorticoid withdrawl syndrome. Am J Med. 68:224-230.
22. Livanou T, Ferriman D, James VHT. 1967 Recovery of hypothalamo-piruitary-adrenal function after corticosteroid therapy. Lancet. 2:856-859.
23. Schlaghecke R, Kornely E, Santen RT, Ridderskamp P. 1992 The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med. 326:226-230.
24. Christy NP. 1992 Pituitary-adrenal function during corticosteroid therapy. N Engl J Med. 326:266-267.
25. Young EA, Kwak SP, Kottak J. 1995 Negative feedback regulation following administration of chronic exogenous corticosterone. J Neuroendocrinol. 7:37-45.
26. Plotsky PM, Sawchenko PE. 1987 Hypophysial-portal plasma levels, median eminence content, and IHC staining of CRF, AVP, and OXT after pharmacological adrenalectomy. Endocrinology. 120:1361-1369.
27. Fink G, Robinson ICAF, Tannahill LA. 1988 Effects of adrenalectomy and glucocorticoids on the peptides CRF-41, AVP and oxytocin in rat hypophysial portal blood. J Physiol. 401:329-345.
28. Imaki T, Xiao-Quan W, Shibasaki T, et al. 1995 Stress-induced activation of neuronal activity and CRF gene expression in the PVN is modulated by glucocorticoids in rats. J Clin Invest. 96:231-238.
29. Eckland DJA, Harbuz MS, Jessop DS, Lightman SL. 1991 CRF and AVP in the hypothalamo-hypophyseal portal blood of rats following high-dose glucocorticoid treatment and withdrawal. Brain Res. 568:311-313.
30. Papanek PE, Raff H. 1994 Physiological increases in Cortisol inhibit basal AVP release in conscious dogs. Am J Physiol. 266:R1744-R1751.
31. Herman JP. 1995 In situ hybridization analysis of AVP gene transcription in the PVN and SON of the rat: regulation by stress and glucocorticoids. J Comp Neurol. 363:15-27.
32. Pralong FP, Linton EA, Favrod-Coune CA, Lowry PJ, Muller AF, Gaillard RC. 1990 Anatomical localization of CRF and AVP in the human hypothalamus: the effect of glucocorticoids on their concentrations in human and rat hypothalami. J Neuroendocrinol. 2:369-374.
33. Erkut ZA, Hofman MA, Ravid R, Swaab DF. 1995 Increased activity of hypothalamic CRH neurons in MS. J Neuroimmunol. 62:27-33.
34. VanOers JWAM, Tilders FJH, Berkenbosch F. 1989 Characterization and biological activity of a monoclonal antibody to rat/human CRH. Endocrinology. 124:1239-1246.
35. Hou-yu A, Lamme AT, Zimmerman EA, Silverman A. 1986 Comparative distribution of vasopressin and oxytocin neurons in the rat brain using a double-label procedure. Neuroendocrinology. 44:235-246.
36. North WG, Pai S, Friedman A, Yu X, Fay M, Memoli V. 1995 Vasopressin gene related products are markers of human breast cancer. Breast Cancer Res Treat. 34:229-235.
37. Raadsheer FC, Tilders FJH, Swaab DF. 1994 Similar age related increase of AVP colocalization in paraventricular CRH neurons in controls and Alzheimer patients. J Neuroendocrinol. 6:131-133.
38. Raadsheer FC, Sluiter AA, Ravid R, Tilders FJH, Swaab DF. 1993 Localization of CRH neurons in the PVN of the human hypothalamus: age-dependent colocalization with AVP. Brain Res. 615:50-62.
39. Ahmed AB, George BC, Gonzales-Auvert C, Dingman JF. 1967 Increased plasma arginine vasopressin in clinical adrenocortical insufficiency and its inhibition by glucosteroids. J Clin Invest. 46:111-123.
40. Raadsheer FC, van Heerikhuize JJ, Lucassen PJ, Hoogendijk WJG, Tilders FJH, Swaab DF. 1995 Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am J Psychiatry. 152:1372-1376.
41. McIntyre HD, Mitchell CA, Bowler SD Armstrong JG, Wooler JA, Cowley DM. 1995 Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens. Thorax. 50:1280-1284.
42. Holt PR, Lowndes DW, Smithies E, Dixon GT. 1990 The effect of an inhaled steroid on the hypothalamic-pituitary-adrenal axis: which tests should be used? Clin Exp Allergy. 20:145-149.
43. Liu X, Wang CA, Chen YZ. 1995 Nongenomic effect of glucocorticoid on the release of arginine vasopressin from hypothalamic slices in rats. Neuroendocrinology. 62:628-633.
44. Dorin RI, Ferries LM, Roberts B, Qualls CR, Veldhuis JD, Lisansky EJ. 1996 Assesment of stimulated and spontaneous adrenocorticotropin secretory dynamics identifies distinct components of cortisol feedback inhibition in healthy humans. J Clin Endocrinol Metab. 81:3883-3891.
45. Berghorn KA, Knapp LT, Hoffman GE, Sherman TG. 1995 Induction of glucocorticoid receptor expression in hypothalamic magnocellular vasopressin neurons during chronic hypoosmolality. Endocrinology. 136:804-807.
46. Biewenga WJ, Rijnberg A, Mol JA. 1991 Osmoregulation of systemic vasopressin release during long-term glucocorticoid excess: a study in dogs with hyperadrenocorticism. Acta Endocrinol (Copenh). 124:583-588.
47. Swaab DF, Purba JS, Hofman MA. 1995 Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome a study of five cases. J Clin Endocrinol Metab. 80:573-579.
48. Ahmed B, Kastin AJ, Banks WA, Zadina JE. 1994 CNS effects of peptides: a cross-listing of peptides and their central actions published in the journal Peptides. 1986-1993. Peptides. 15:1105-1155.
49. Menzaghi F, Heinrichs SC, Pich EM, Weiss F, Kobb GF. 1993 The role of limbic and hypothalamic corticotropin-releasing factor in behavioral responses to stress. Ann NY Acad Sci. 697:142-154.
50. Engelmann M, Ludwig M, Landgraf R. 1994 Simultaneous monitoring of intracerebral release and behaviour: endogenous vasopressin improves social recognition. J Neuroendocrinol. 6:391-395.
51. Wik G. 1996 Energy metabolism in the hypothalamus and plasma cortisol levels in patients with schizophrenia. Horm Metab Res. 28:205-206.
52. Bentson J, Reza M, Winter J, Wilson G. 1978 Steroids and apparent cerebral atrophy on computed tomography scans. J Comput Assist Tomogr. 2:16-23.
53. Thomas HA, Ling N, Wei ET. 1993 CRF and related peptides as anti-inflammatory agonists. Ann NY Acad Sci. 697:219-232.
54. Leu SJC, Singh VK. 1993 Suppression of in vitro antibody production by corticotropin-releasing factor neurohormone. J Neuroimmunol. 45:23-30.
55. Irwin M. 1994 Stress-induced immune suppression: role of brain CRH and autonomic nervous system mechanisms. Adv Neuroimmunol. 4:29-47.
56. Mastorakos G, Bouzas EA, Silver PB, et al. 1995 Immune CRH is present in the eyes of and promotes experimental autoimmune uveoretinitis in rodents. Endocrinology. 136:4650-4658.
57. Correa SG, Riera CM, Spiess J, Bianco ID. 1997 Modulation of the inflammatory response by CRF. Eur J Pharmacol. 319:85-90.